Rose-Jones Lisa J, Bode Weeranun D, Gehi Anil K
Advanced Heart Failure & Pulmonary Hypertension, UNC Heart & Vascular Center, 6th Floor, Burnett-Womack Building, 160 Dental Circle, CB#7075, Chapel Hill, NC 27599, USA.
Clinical Fellow, UNC Heart & Vascular Center, 6th Floor, Burnett-Womack Building, 160 Dental Circle, CB#7075, Chapel Hill, NC 27599, USA.
Heart Fail Clin. 2014 Oct;10(4):635-52. doi: 10.1016/j.hfc.2014.07.010. Epub 2014 Aug 14.
Atrial fibrillation (AF) is exceedingly common in patients with heart failure (HF), as they share common risk factors. Rate control is the cornerstone of treatment for AF; however, restoration of sinus rhythm should be considered when more than minimal symptoms are present. Life-threatening ventricular arrhythmias are responsible for the primary mode of death in patients with NYHA I, II, or III HF. Although implantable cardioverter defibrillators protect against sudden cardiac arrest, many patients will present with VT or ICD shocks. Antiarrhythmic drug therapy beyond beta-blocker therapy remains fundamental to the termination of acute VT and the prevention of ICD shocks.
心房颤动（AF）在心力衰竭（HF）患者中极为常见，因为它们有共同的危险因素。心率控制是房颤治疗的基石；然而，当出现超过轻微症状时，应考虑恢复窦性心律。危及生命的室性心律失常是纽约心脏协会I、II或III级心力衰竭患者的主要死亡原因。尽管植入式心脏复律除颤器可预防心脏骤停，但许多患者仍会出现室性心动过速（VT）或植入式心脏复律除颤器（ICD）电击。除β受体阻滞剂治疗外，抗心律失常药物治疗仍然是终止急性室性心动过速和预防植入式心脏复律除颤器电击的基础。
